Table of Content

1. Report Introduction

2. Relapsing Refractory Multiple Myeloma
2.1. Overview
2.2. History
2.3. Relapsing Refractory Multiple Myeloma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Relapsing Refractory Multiple Myeloma Diagnosis
2.6.1. Diagnostic Guidelines

3. Relapsing Refractory Multiple Myeloma Current Treatment Patterns
3.1. Relapsing Refractory Multiple Myeloma Treatment Guidelines

4. Relapsing Refractory Multiple Myeloma - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Relapsing Refractory Multiple Myeloma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Relapsing Refractory Multiple Myeloma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Relapsing Refractory Multiple Myeloma Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Relapsing Refractory Multiple Myeloma Late Stage Products (Phase-III)

7. Relapsing Refractory Multiple Myeloma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Relapsing Refractory Multiple Myeloma Discontinued Products

13. Relapsing Refractory Multiple Myeloma Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?

14. Relapsing Refractory Multiple Myeloma Key Companies

15. Relapsing Refractory Multiple Myeloma Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Relapsing Refractory Multiple Myeloma Unmet Needs

18. Relapsing Refractory Multiple Myeloma Future Perspectives

19. Relapsing Refractory Multiple Myeloma Analyst Review

20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation



List of Figures


Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Relapsing Refractory Multiple Myeloma companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Relapsing Refractory Multiple Myeloma Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs


List of Tables


Table 1: Relapsing Refractory Multiple Myeloma Diagnostic Guidelines
Table 2: Relapsing Refractory Multiple Myeloma Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Relapsing Refractory Multiple Myeloma Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Relapsing Refractory Multiple Myeloma Late Stage Products (Phase-III)
Table 18: Relapsing Refractory Multiple Myeloma Mid Stage Products (Phase-II)
Table 19: Relapsing Refractory Multiple Myeloma Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products